Sylvain Lesné Neuroscientifique français
Lesné, Sylvain 1974-...
VIAF ID: 208843339 (Personal)
Permalink: http://viaf.org/viaf/208843339
Preferred Forms
4xx's: Alternate Name Forms (7)
Works
Title | Sources |
---|---|
Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. | |
Akt-dependent expression of NAIP-1 protects neurons against amyloid-{beta} toxicity | |
Amyloid plaques and amyloid-beta oligomers: an ongoing debate. | |
The amyloid-β oligomer Aβ*56 induces specific alterations in neuronal signaling that lead to tau phosphorylation and aggregation. | |
Angiopoietin-1-induced PI3-kinase activation prevents neuronal apoptosis. | |
Bidirectional modulation of Alzheimer phenotype by alpha-synuclein in mice and primary neurons | |
Cellular prion protein and class-specific Aβ oligomers mediate plaque-associated cytopathology in a mouse model of Alzheimer’s disease | |
Cognitive effects of cell-derived and synthetically derived Aβ oligomers | |
The complex PrP(c)-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease | |
Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity | |
Detecting aβ*56 oligomers in brain tissues. | |
[Does transforming growth factor-beta | |
Gain-of-function mutations in protein kinase Cα (PKCα) may promote synaptic defects in Alzheimer's disease | |
Genetic modulation of soluble Aβ rescues cognitive and synaptic impairment in a mouse model of Alzheimer's disease | |
Involvement of beta-site APP cleaving enzyme 1 (BACE1) in amyloid precursor protein-mediated enhancement of memory and activity-dependent synaptic plasticity. | |
Ischemia-Induced Interleukin-6 as a Potential Endogenous Neuroprotective Cytokine against NMDA Receptor-Mediated Excitoxicity in the Brain | |
Live discussion: Amyloid-beta degradation: the forgotten half of Alzheimer's disease. 12 September 2002. | |
NMDA receptor activation inhibits alpha-secretase and promotes neuronal amyloid-beta production. | |
Oligomers of the amyloid-beta protein disrupt working memory: confirmation with two behavioral procedures. | |
Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. | |
Plaque-bearing mice with reduced levels of oligomeric amyloid-beta assemblies have intact memory function. | |
Reduced brain tissue perfusion in TGF-beta 1 transgenic mice showing Alzheimer's disease-like cerebrovascular abnormalities | |
Régulation d'expression et du métabolisme d'APP au cours des pathologies dégénératives | |
Selective lowering of synapsins induced by oligomeric α-synuclein exacerbates memory deficits | |
Soluble Aβ oligomer production and toxicity | |
Soluble Conformers of Aβ and Tau Alter Selective Proteins Governing Axonal Transport | |
Soluble endogenous oligomeric α-synuclein species in neurodegenerative diseases: Expression, spreading, and cross-talk | |
Soluble α-synuclein is a novel modulator of Alzheimer's disease pathophysiology | |
Sp1 and Smad transcription factors co-operate to mediate TGF-beta-dependent activation of amyloid-beta precursor protein gene transcription. | |
A specific amyloid-beta protein assembly in the brain impairs memory | |
Tau is required for progressive synaptic and memory deficits in a transgenic mouse model of α-synucleinopathy | |
Toxic oligomer species of amyloid-β in Alzheimer's disease, a timing issue. |